Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer (CyPath® Lung) and other lung diseases using flow cytometry and AI. It also advances therapeutic discoveries for skin cancer. Operations include a wholly-owned clinical pathology laboratory (PPLS) and R&D activities.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net Revenue | $2,862,106 | $3,123,080 |
| Net Loss | $(6,996,692) | $(6,721,204) |
| Loss Per Share (Basic & Diluted) | $(1.44) | $(10.01) |
| Cash and Cash Equivalents (End of Period) | $2,429,719 | $802,835 |
| Accumulated Deficit | $(75,550,756) | $(60,365,514) |
| Net Cash Used in Operating Activities | $(6,428,344) | $(4,288,981) |
| Net Cash Provided by Financing Activities | $2,503,914 | $4,050,738 |
Debt and Liquidity: Total liabilities were $3.85 million. Current liabilities include $969,845 in accounts payable and $1.41 million in accrued expenses. The Company raised approximately $3.2 million in gross proceeds from a public offering in June 2026.
Material Changes vs. Prior Period
- Revenue Composition: While total consolidated revenue decreased 8% year-over-year due to the discontinuation of unprofitable pathology services, revenue from the CyPath® Lung diagnostic test increased 156% to $835,000 for the six-month period.
- Operating Expenses: Total operating expenses increased 19% to $9.8 million. This was driven by a 203% increase in clinical development expenses ($810k vs $268k) due to the activation of 11 clinical trial sites, and a 31% increase in SG&A expenses due to stock-based compensation and sales expansion.
- Net Loss Improvement: Despite higher operating expenses, the net loss per share improved significantly from $(10.01) to $(1.44) due to a substantial increase in the weighted average shares outstanding (from 671,529 to 4,860,753) following equity issuances.
- Other Income/Expense: Net other expense decreased significantly from $(1.54) million to $(45k), primarily because the prior year included a $(1.06) million loss on the remeasurement of warrant liabilities, which did not recur in the current period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months. Cash on hand ($2.4 million) is projected to support operations only through August 2026. Additional capital is required to fund operations and clinical trials.
- Nasdaq Delisting Risk: The Company received notice from Nasdaq regarding failure to maintain the $1.00 minimum bid price requirement. An appeal hearing was requested in August 2026 to stay delisting actions.
- Recent Developments:
- Collaboration announced with Pictor, Inc. for next-generation diagnostic tests.
- 11 clinical sites activated for the CyPath® Lung longitudinal trial, including VA and military centers.
- Positive preliminary results presented for topical skin cancer therapeutics.
- Unusual Items: An immaterial error correction regarding a lease amendment was recorded in Q1 2026, resulting in a $28,000 expense adjustment.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise, as management states cash may only last through August 2026.
- Nasdaq Compliance: Monitor the outcome of the Nasdaq hearing appeal regarding the minimum bid price requirement.
- Revenue Sustainability: Assess the growth trajectory of CyPath® Lung revenue against the discontinuation of other pathology services to determine if the core product can offset operating losses.
- Dilution Impact: Review the impact of recent equity offerings (June 2026) and outstanding warrants (1.83 million) on future shareholder dilution.
- Clinical Trial Progress: Track patient enrollment rates at the 11 activated clinical sites to validate the increased clinical development spend.